BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
BridgeBio Pharma presented positive preliminary data from eleven participants in the CANaspire Phase 1/2 clinical trial of BBP-812, an investigational gene therapy for Canavan disease. The study showed significant motor function improvements and milestone achievements at 12-months post-treatment, contrasting with the natural disease progression observed in their CANinform study.
Key findings include sustained reductions in N-acetylaspartate levels across urine, cerebrospinal fluid, and brain, with urine NAA reduced by 64% in low dose and 73% in high dose cohorts. The therapy demonstrated improved myelination and continued motor function progress, with some children achieving independent sitting and walking. BBP-812 was generally well-tolerated and has received multiple FDA designations including RMAT, Orphan Drug, and Fast Track.
BridgeBio Pharma ha presentato dati preliminari positivi da undici partecipanti nel trial clinico di fase 1/2 CANaspire per BBP-812, una terapia genica in fase di sperimentazione per la malattia di Canavan. Lo studio ha mostrato significativi miglioramenti della funzione motoria e risultati raggiunti a 12 mesi dopo il trattamento, in contrasto con la progressione naturale della malattia osservata nel loro studio CANinform.
I risultati chiave includono riduzioni sostenute dei livelli di N-acetilaspartato nelle urine, nel liquido cerebrospinale e nel cervello, con una riduzione del NAA urinario del 64% nei gruppi a bassa dose e del 73% nei gruppi ad alta dose. La terapia ha dimostrato un miglioramento della mielinizzazione e progressi continui nella funzione motoria, con alcuni bambini in grado di sedersi e camminare autonomamente. BBP-812 è stato generalmente ben tollerato e ha ricevuto molteplici designazioni dalla FDA, tra cui RMAT, Farmaco Orfano e Percorso Veloce.
BridgeBio Pharma presentó datos preliminares positivos de once participantes en el ensayo clínico de fase 1/2 CANaspire de BBP-812, una terapia génica en investigación para la enfermedad de Canavan. El estudio mostró mejoras significativas en la función motora y logros importantes a los 12 meses después del tratamiento, en contraste con la progresión natural de la enfermedad observada en su estudio CANinform.
Los hallazgos clave incluyen reducciones sostenidas en los niveles de N-acetilaspártico en la orina, líquido cefalorraquídeo y cerebro, con una reducción del NAA urinario del 64% en los grupos de baja dosis y del 73% en los grupos de alta dosis. La terapia demostró una mejoría en la mielinización y un progreso continuo en la función motora, con algunos niños logrando sentarse y caminar de manera independiente. BBP-812 fue generalmente bien tolerado y ha recibido múltiples designaciones de la FDA, incluyendo RMAT, Medicamento Huérfano y Vía Rápida.
BridgeBio Pharma는 Canavan병에 대한 연구용 유전자 치료제인 BBP-812의 CANaspire 1/2상 임상시험에서 11명의 참가자로부터 긍정적인 초기 데이터를 발표했습니다. 연구 결과는 치료 후 12개월에 중요한 운동 기능 개선과 이정표 성취를 보여주었으며, 이는 CANinform 연구에서 관찰된 자연질병 진행과 대조적입니다.
주요 발견으로는 소변, 뇌척수액 및 뇌에서 N-아세틸아스파르트산(NAA) 수치가 지속적으로 감소했으며, 소변 NAA는 저용량 코호트에서 64%, 고용량 코호트에서 73% 감소했습니다. 이 치료는 수초화가 개선되고 지속적인 운동 기능 향상이 나타났으며, 일부 어린이는 독립적으로 앉고 걷는 능력을 이루었습니다. BBP-812는 일반적으로 잘 견디어냈고 RMAT, 고아약 및 신속 심사 등 FDA의 여러 지정을 받았습니다.
BridgeBio Pharma a présenté des données préliminaires positives provenant de onze participants dans l'essai clinique de phase 1/2 CANaspire concernant BBP-812, une thérapie génique expérimentale pour la maladie de Canavan. L'étude a montré des améliorations significatives de la fonction motrice et des accomplissements importants à 12 mois après le traitement, contrastant avec la progression naturelle de la maladie observée dans leur étude CANinform.
Les principales conclusions comprennent des réductions soutenues des niveaux de N-acétylaspartate dans l'urine, le liquide céphalorachidien et le cerveau, avec une réduction de NAA urinaire de 64 % dans les cohortes à faible dose et de 73 % dans les cohortes à forte dose. La thérapie a montré une amélioration de la myélinisation et une progression continue de la fonction motrice, certains enfants ayant réussi à s'asseoir et à marcher de manière autonome. BBP-812 a été généralement bien toléré et a reçu plusieurs désignations de la FDA, notamment RMAT, médicament orphelin et voie rapide.
BridgeBio Pharma hat positive vorläufige Daten von elf Teilnehmern aus der CANaspire-Phase-1/2-Studie von BBP-812, einer experimentellen Gentherapie für die Canavan-Krankheit, präsentiert. Die Studie zeigte signifikante Verbesserungen der motorischen Funktionen und das Erreichen von Meilensteinen 12 Monate nach der Behandlung, im Gegensatz zum natürlichen Krankheitsverlauf, der in ihrer CANinform-Studie beobachtet wurde.
Zu den wichtigsten Ergebnissen gehören anhaltende Reduzierungen der N-Acetylaspartat-Spiegel in Urin, Hirnwasser und Gehirn, wobei der Urin-NAA um 64 % in der Niedrigdosisgruppe und um 73 % in der Hochdosisgruppe reduziert wurde. Die Therapie zeigte verbesserte Myelinisierung und fortlaufende Fortschritte in der motorischen Funktion, wobei einige Kinder in der Lage waren, unabhängig zu sitzen und zu gehen. BBP-812 wurde im Allgemeinen gut vertragen und erhielt mehrere FDA-Bezeichnungen, darunter RMAT, Orphan Drug und Fast Track.
- None.
- None.
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the disease course observed in BridgeBio’s ongoing CANinform natural history comparator study
- Significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose; encouraging trends of further reduction in urine NAA in participants who received high dose BBP-812
- If approved, BridgeBio’s gene therapy for Canavan disease could be the first therapeutic option for children born with this fatal neurodevelopmental disorder
PALO ALTO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio ), a commercial-stage biopharmaceutical company focused on genetic diseases, presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy in development for the treatment of Canavan disease. Preliminary results from the study were presented in an invited, peer reviewed talk by the study’s principal investigator, Dr. Florian Eichler, M.D., director of the leukodystrophy service at Massachusetts General Hospital, Center for Rare Neurological Disease and principal investigator of CANaspire, today at the 31st Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Rome, Italy.
“We continue to be encouraged by the results children are achieving in the CANaspire trial of BBP-812,” said Dr. Eichler. “Compared to the natural course of Canavan disease, in which most children do not achieve developmental milestones beyond that of a 6-month old, the fact that some children are sitting independently, taking steps, or even walking post-dosing is truly remarkable.”
CANaspire is a Phase 1/2 open-label study designed to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, in pediatric patients with Canavan disease. CANinform is an ongoing natural history study of more than 60 patients with Canavan disease, which was designed as a robust comparator for the CANaspire study in accordance with FDA’s guidance on the design and conduct of externally controlled trials. Highlights of the results presented at ESGCT 2024 include:
- Rapid and sustained reduction of NAA in urine and brain of participants post BBP-812 dosing
- Urine NAA was reduced to levels associated with mild Canavan disease (average reduction of
64% +/-14% twelve months after receiving low dose and73% +/-13% three months after the high dose) - NAA in CSF was reduced an average of
70% +/-10% twelve months after receiving the low dose. Lower urine NAA levels have been maintained for nearly 3 years in the earliest dosed participants
- Urine NAA was reduced to levels associated with mild Canavan disease (average reduction of
- Improved myelination on T-2-weighted magnetic resonance imaging (MRI) observed in the majority of participants dosed with BBP-812
- Progressive and continued post-dose improvement in gross motor function (measured by Gross Motor Function Measure (GMFM)-88) and achievement of motor milestones (measured by Hammersmith Infant Neurological Examination (HINE)-2)
- This trajectory of progressive improvement stands in stark contrast to the characterized natural history of the disease, where the trajectory over this time period is essentially flat
- In the low-dose cohort, these divergent trajectories result in statistically significant improvements in achieved motor function and milestones at 12-months after treatment with BBP-812, compared to what is observed in and predicted by the natural history of the disease; data from the high dose cohort are not yet available
- All participants demonstrated progress on administered developmental/motor assessments as measured by the GMFM-88, HINE-2, CDC milestones, or the Canavan Disease Rating Scale
- BBP-812 continues to be generally well-tolerated, with a safety profile consistent with other systemically administered AAV9 gene therapies
BBP-812 has been granted Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, Rare Pediatric Disease (RPDD), and Fast Track Designations from the FDA, as well as Orphan Drug Designation from the European Medicines Agency. With RPDD, if approved, BridgeBio may qualify for a PRV.
About CANaspire
CANaspire is a Phase 1/2 open-label study designed to evaluate the safety, tolerability, and pharmacodynamic activity of BridgeBio’s AAV9 gene therapy candidate, BBP-812, in pediatric patients with Canavan disease. Each eligible patient will receive a single IV infusion of BBP-812. The primary outcomes of the study are safety, as well as change from baseline of urine and central nervous system NAA levels. Motor function and development will also be assessed.
For more information about the CANaspire trial, visit TreatCanavan.com or ClinicalTrials.gov (NCT04998396).
About Canavan Disease
Affecting approximately 1,000 children in the U.S. and European Union, Canavan disease is an ultra-rare, disabling and fatal disease with no approved therapy. Most children are not able to meet developmental milestones, are unable to crawl, walk, sit or talk, and die at a young age. The disease is caused by an inherited mutation of the ASPA gene that codes for aspartoacylase, a protein that breaks down a compound called NAA. Deficiency of aspartoacylase activity results in accumulation of NAA, and ultimately results in toxicity to myelin in ways that are not currently well understood. Myelin insulates neuronal axons, and without it, neurons are unable to send and receive messages as they should. The current standard of care for Canavan disease is limited to supportive therapy.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements. Statements BridgeBio makes in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements relating to expectations, plans and prospects regarding BridgeBio’s regulatory approval process for BBP-812, the ability of BBP-812 to be the first therapeutic treatment option for children born with Canavan disease and eligibility for a PRV, reflect BridgeBio’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to BridgeBio and on assumptions BridgeBio has made. Although BridgeBio believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, BridgeBio can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, BridgeBio’s ability to continue and complete its Phase 1/2 clinical trial of BBP-812 for the treatment of Canavan disease, BridgeBio’s ability to advance BBP-812 in clinical development according to its plans, the ability of BBP-812 to treat Canavan disease, the ability of BBP-812 to retain Fast Track Designation, RPDD, RMAT and Orphan Drug Designation from the FDA and Orphan Drug Designation from the European Medicines Agency, and potential adverse impacts due to global health emergencies, including delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation and rising interest rates, on our business operations and expectations as well as those risks set forth in the Risk Factors section of BridgeBio’s most recent Annual Report on Form 10-K, and BridgeBio’s other filings with the U.S. Securities and Exchange Commission. Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of BridgeBio’s management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
What are the key results from BridgeBio's (BBIO) CANaspire Phase 1/2 trial for Canavan disease?
How effective is BridgeBio's (BBIO) BBP-812 gene therapy in treating Canavan disease?
What regulatory designations has BridgeBio (BBIO) received for BBP-812?
What safety profile does BridgeBio's (BBIO) BBP-812 show in the CANaspire trial?
